Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

$14.98 +0.08 (+0.54%)

Closing price 04/2/2025 03:59 PM Eastern

Extended Trading

$15.44 +0.46 (+3.10%)

As of 05:11 AM Eastern

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 1 Analyst Ratings

Sell
0

Hold
0

Buy
1

Based on 1 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for TAK.

Consensus Price Target

N/A

Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

TAK Analyst Ratings Over Time

Type	Current Forecast 4/3/24 to 4/3/25	1 Month Ago 3/4/24 to 3/4/25	3 Months Ago 1/4/24 to 1/3/25	1 Year Ago 4/4/23 to 4/3/24
Strong Buy	0 Strong Buy rating(s)	N/A	N/A	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	N/A	N/A	1 Buy rating(s)
Hold	0 Hold rating(s)	N/A	N/A	0 Hold rating(s)
Sell	0 Sell rating(s)	N/A	N/A	0 Sell rating(s)
Consensus Price Target	N/A	N/A	N/A	$22.00
Forecasted Upside	N/A	N/A	N/A	62.60% Upside
Consensus Rating	Buy	N/A	N/A	Buy

Remove Ads

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Takeda Pharmaceutical Stock vs. The Competition

Type	Takeda Pharmaceutical	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	19,033.05% Upside	17.77% Upside
News Sentiment Rating	Positive News See Recent TAK News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
4/2/2025	Morgan Stanley 3 of 5 stars	Upgrade	Equal Weight ➝ Overweight
9/1/2023	JPMorgan Chase & Co. 3 of 5 stars	Lower Target		$14.20 ➝ $14.00	-9.06%
4/4/2023	TD Cowen 4 of 5 stars	Boost Target	Outperform	$24.00 ➝ $30.00	+79.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:11 AM ET.

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, March 28, 2025. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

Takeda Pharmaceutical Company Limited recently reached a new 52-week high, trading at $15.08, indicating strong market performance and investor confidence.
The company reported earnings per share (EPS) of $0.42, surpassing the consensus estimate of $0.34, which reflects better-than-expected profitability and operational efficiency.
With a market capitalization of approximately $48.29 billion, Takeda Pharmaceutical Company Limited is positioned as a significant player in the pharmaceutical industry, suggesting stability and growth potential.
The firm has a low debt-to-equity ratio of 0.63, indicating a manageable level of debt relative to its equity, which can be attractive to investors looking for financially sound companies.
Institutional investors hold 9.17% of the stock, which can be a positive signal as these investors typically conduct thorough research before making investment decisions.

Takeda Pharmaceutical
Bear Case

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

The company has a relatively high price-to-earnings (P/E) ratio of 37.94, which may indicate that the stock is overvalued compared to its earnings, potentially leading to lower returns for investors.
Despite recent positive earnings, the net margin of 4.53% suggests that the company may face challenges in converting revenue into actual profit, which could impact future growth.
The quick ratio of 0.72 indicates that the company may have difficulty meeting its short-term liabilities with its most liquid assets, raising concerns about liquidity.
Recent trading volumes have shown fluctuations, with a significant drop from an average of 1,826,343 shares to 773,113 shares, which may indicate reduced investor interest or confidence.
Analysts project an EPS of 1.64 for the current fiscal year, which may not be sufficient to justify the current stock price, leading to potential investor disappointment.

TAK Forecast - Frequently Asked Questions

: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TAK shares.
: According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Takeda Pharmaceutical's stock had 1 upgrade by analysts.
: Takeda Pharmaceutical has been rated by research analysts at Morgan Stanley in the past 90 days.
: Analysts like Takeda Pharmaceutical more than other "medical" companies. The consensus rating for Takeda Pharmaceutical is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TAK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:TAK) was last updated on 4/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target